Biphosphonate-related osteonecrosis of the jaw in cancer patients and hyperbaric oxygen therapy

Journal of the Pancreas

Volumn 10, Issue 5, 2009, Pages 579-580

  Erkan, Mustafa ^a   Bilgi, Oǧuz ^a   Mutluoglu, Mesut ^a   Uzun, Günalp ^a  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; OXYGEN;

BONE TURNOVER; CANCER PATIENT; HUMAN; HYPERBARIC OXYGEN; INCIDENCE; JAW OSTEONECROSIS; LETTER; METASTASIS POTENTIAL; PANCREAS ADENOCARCINOMA; WOUND HEALING; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; EVALUATION; JAW DISEASE; NEOPLASM; NOTE; TREATMENT OUTCOME;

DIPHOSPHONATES; HUMANS; HYPERBARIC OXYGENATION; INCIDENCE; JAW DISEASES; NEOPLASMS; OSTEONECROSIS; TREATMENT OUTCOME;

EID: 70349292677     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Letter

References (14)

1. Smith A, Kressley A, Saif MW. Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases. JOP. 2009; 10(2):212-4.
2. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61(9):1115-7.
3. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007; 65(3):369-76.
4. Rayman S, Almas K, Dincer E. Bisphosphonate-related jaw necrosis: a team approach management and prevention. Int J Dent Hyg. 2009; 7(2):90-5.
5. Marx RE. Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws. History, etiology, prevention, and treatment. Quintessence Publishing Co Inc; 2007. p. 9-96.
6. Lam DK, Sándor GK, Holmes HI, Evans AW, Clokie CM. A review of bisphosphonate-associated osteonecrosis of the jaws and its management. J Can Dent Assoc. 2007; 73(5):417-22.
7. Feldmeier JJ, Hampson NB. A systematic review of the literature reporting the application of hyperbaric oxygen prevention and treatment of delayed radiation injuries: an evidence based approach. Undersea Hyperb Med. 2002; 29(1):4-30.
8. Freiberger J, Padila-Burgos R, Chhoeu AH, Kraft KH, Boneta O, Moon RE, Piantodosi CA. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: A case series. J Oral Maxillofac Surg 2007; 65(7):1321-7.
9. Shimura K, Shimazaki C, Taniguchi K, Akamatsu S, Okamoto M, Uchida R, et al. Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonate-induced osteonecrosis of the jaw in a patient with multiple myeloma. Int J Hematol 2006; 84(4):343-5.
10. Lee CY, David T, Nishime M. Use of platelet-rich plasma in the management of oral biphosphonate-associated osteonecrosis of the jaw: a report of 2 cases. J Oral Implantol. 2007; 33(6):371-82.
11. Magopoulos C, Karakinaris G, Telioudis Z, Vahtsevanos K, Dimitrakopoulos I, Antoniadis K, Delaroudis S. Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals. Am J Otolaryngol. 2007; 28(3):158-63.
12. Freiberger JJ. Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009; 67(5 Suppl):96-106.
13. Feldmeier JJ, Heimbach RD, Davolt DA, Brakora MJ. Hyperbaric oxygen and the cancer patient: a survey of practice patterns. Undersea Hyperb Med. 1993; 20(4):337-45.
14. Feldmeier J, Carl U, Hartmann K, Sminia P. Hyperbaric oxygen: does it promote growth or recurrence of malignancy? Undersea Hyperb Med. 2003; 30(1):1-18.